Septerna, Inc.
SEPN
Positions held
Your positionsSEPN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Septerna, Inc. operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, positioning the company well for future growth.
- The company's market cap stands at approximately $1.66 billion, indicating a solid presence in the market.
- Septerna has a strong buy recommendation, with a target mean price of $54.22, suggesting significant upside potential.
- The company has a high debt-to-equity ratio of 5.83, indicating potential financial risk.
- In the most recent quarter, Septerna reported a revenue of $26.746 million, but the operating margin was heavily negative at -62.95%.
- The profit margin is currently at -24.51%, reflecting ongoing challenges in achieving profitability.
Fundamentals
| Market cap | $1.72B | Enterprise value | $1.37B | Trailing P/E | — | Forward P/E | -19.01 |
| PEG | — | Price / book | 4.36 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 223.8% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -62.9% |
| Profit margin | -24.5% | ROE | -6.3% | ROA | -7.1% | Debt / equity | 0.06 |
| Current ratio | 5.00 | Free cash flow | $29.54M | Analyst recommendation | strong_buy | Mean target | $54.22 |
| 52w high | $51.10 | 52w low | $17.55 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $26.7M | $26.5M | $24.1M | $21.5M | $0.1M | — |
| Op margin | -62.9% | -50.1% | -66.4% | -46.0% | -24351.3% | — |
| Net income | -$13.0M | -$8.6M | -$10.7M | $8.2M | -$24.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.8M | -$13.3M | -$16.0M | -$9.9M | -$29.0M | — |
- Revenue +1% vs prior quarter ($27M vs $27M).
- Operating margin compressed to -63%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $46.0M | $1.1M | $0.2M | $0.0M |
| Op margin | -175.8% | -7518.4% | -30165.6% | — |
| Net income | -$48.9M | -$71.8M | $4.2M | -$27.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$80.8M | -$80.8M | -$45.5M | -$28.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
2026-09-10 · Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 · Septerna to Participate in Upcoming Investor Conferences
2026-08-25 · Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
2026-08-10 · Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
2026-08-10 · Septerna Q2 Loss Narrows, Revenue Rises
2026-08-10 · Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
2026-08-05 · Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns